- Home
- PRSU vs PHVS Comparison
PRSU vs PHVS Comparison
Compare PRSU & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRSU
- PHVS
- Stock Information
- Founded
- PRSU 1926
- PHVS 2015
- Country
- PRSU United States
- PHVS Netherlands
- Employees
- PRSU N/A
- PHVS N/A
- Industry
- PRSU Business Services
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- PRSU Consumer Discretionary
- PHVS Health Care
- Exchange
- PRSU Nasdaq
- PHVS Nasdaq
- Market Cap
- PRSU 876.5M
- PHVS 1.0B
- IPO Year
- PRSU N/A
- PHVS 2021
- Fundamental
- Price
- PRSU $39.74
- PHVS $17.11
- Analyst Decision
- PRSU
- PHVS Strong Buy
- Analyst Count
- PRSU 0
- PHVS 5
- Target Price
- PRSU N/A
- PHVS $41.60
- AVG Volume (30 Days)
- PRSU 200.6K
- PHVS 49.2K
- Earning Date
- PRSU 03-04-2025
- PHVS 11-13-2024
- Dividend Yield
- PRSU N/A
- PHVS N/A
- EPS Growth
- PRSU 58.18
- PHVS N/A
- EPS
- PRSU 1.06
- PHVS N/A
- Revenue
- PRSU $1,399,418,000.00
- PHVS N/A
- Revenue This Year
- PRSU $11.65
- PHVS N/A
- Revenue Next Year
- PRSU $0.72
- PHVS N/A
- P/E Ratio
- PRSU $37.52
- PHVS N/A
- Revenue Growth
- PRSU 17.10
- PHVS N/A
- 52 Week Low
- PRSU $29.46
- PHVS $15.21
- 52 Week High
- PRSU $47.49
- PHVS $33.00
- Technical
- Relative Strength Index (RSI)
- PRSU N/A
- PHVS 38.75
- Support Level
- PRSU N/A
- PHVS $17.11
- Resistance Level
- PRSU N/A
- PHVS $18.70
- Average True Range (ATR)
- PRSU 0.00
- PHVS 1.10
- MACD
- PRSU 0.00
- PHVS -0.07
- Stochastic Oscillator
- PRSU 0.00
- PHVS 34.65
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.